In a move approved unanimously by the Board of Directors of both companies, pest control and cannabis media industry leader Med-X, Inc. (“Med-X”) has announced that they have entered into a definitive merger and acquisition agreement with Pacific Shore Holdings, Inc. (“PSH”), a global green pest control company and over-the-counter (“OTC”) pharmacy products supplier. The combined company brings together best-in-class product, technology and service capabilities across the media, pest control, pain management, aromatherapy and essential oil manufacturing industries.
The company will retain the Med-X name and will launch the brand into the future of the development of commercial and consumer products, integrated pest management services and pain management solutions.
“The combination of Med-X and PSH represents the next stage of our continued growth to become a global leader in green medicine technologies,” stated Dr. David E. Toomey, Chief Executive Officer, Med-X, Inc. “With its international and domestic distribution partnerships in place, PSH aligns with and enhances the Med-X cannabis platform and further positions all of our business divisions for long term growth. Through this transaction, we will also expand our ability to move both within and outside of the cannabis space, which we feel will increase shareholder value in both short and long term,” stated Dr. Toomey.
The newly merged company will also benefit consumers and shareholders alike by combining trade secrets and essential oil blending techniques for new products, advanced service solutions already proven effective in other industries, and value-added assets like patents, trademarks, intellectual properties and connectivity with mainstream distributors like Cardinal Health, Independence Medical, Target Specialty Products and Rentokil.
“We expect this transaction, combined with our growth plans for 2018 and beyond, to propel the combined company forward internationally. It should also fuel our continued efforts with our Regulation A+ Crowdfunding initiative, which allows everyday Americans to participate with an investment of $420 for 700 shares in the company. This transaction should offer greater value to our shareholders, customers and employees” explained Med-X, Inc. President and Chief Operating Officer, Matthew Mills.
When it comes to the cannabis cultivation industry, Med-X is positioned even better to lead the way from the use of harmful chemicals in growing and in making high-quality medicine for patients in many states and toward a safer, more consistent and all-natural way of providing cannabis products to consumers.
The future is bright for Med-X!
